Journal
HEART FAILURE REVIEWS
Volume 18, Issue 2, Pages 135-140Publisher
SPRINGER
DOI: 10.1007/s10741-011-9295-6
Keywords
Heart failure; Cardiorenal; Ace inhibitor; Angiotensin receptor blocker; Acute kidney disease; Chronic kidney disease; Worsening renal function
Categories
Funding
- Bayer Schering Pharma AG
- DebioPharm S.A.
- Medtronic
- Novartis Pharma AG
- Otsuka Pharmaceuticals
- Sigma Tau
- Solvay Pharmaceuticals
- Pericor Therapeutics
Ask authors/readers for more resources
Heart failure syndromes are often associated with multi-organ dysfunction, and concomitant liver, renal, and neurologic involvement is very common. Neuro-hormonal antagonism plays a key role in the management of this syndrome, and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are one of the cornerstones of therapy. Cardiorenal physiology is becoming more recognized in these patients with advanced heart failure, and the role of neuro-hormonal blockade in this setting is vaguely defined in the literature. Often, angiotensin-converting enzyme inhibitors are decreased or even withheld in these circumstances. The purpose of this article is to review the role and pathophysiology of ace inhibition and angiotensin receptor blockade in patients with acute and chronic heart failure syndromes and concomitant cardiorenal physiology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available